Dr. Frederick D. Min, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 735
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2000Medical school: University of South Carolina School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D68686
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Holy Cross Hospital Silver Spring, MD
- Adventist Healthcare White Oak Medical Center Silver Spring, MD
Medical groups
- Maryland Oncology Hematology PA (104 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 735
- Services billed
- 324,038
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 66,750 | 86 |
| Injection, pembrolizumab, 1 mg | 25,600 | 25 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 23,220 | 16 |
| Injection, denosumab, 1 mg | 20,760 | 119 |
| Injection, ferric carboxymaltose, 1 mg | 20,250 | 17 |
| Injection, aprepitant, 1 mg | 18,720 | 47 |
| Injection, iron sucrose, 1 mg | 17,400 | 41 |
| Injection, paclitaxel, 1 mg | 13,902 | 17 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,240 | 15 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11,700 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Silver Spring, MD | 111 |
| Acyclovir Other prescribers in Silver Spring, MD | 69 |
| Xarelto (rivaroxaban) Other prescribers in Silver Spring, MD | 64 |
| Dexamethasone Other prescribers in Silver Spring, MD | 55 |
| Brukinsa (zanubrutinib) | 38 |
| Warfarin Sodium Other prescribers in Silver Spring, MD | 35 |
| Lynparza (olaparib) | 35 |
| Prednisone Other prescribers in Silver Spring, MD | 33 |
| Letrozole Other prescribers in Silver Spring, MD | 31 |
| Abiraterone Acetate | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 40 companies reported 99 payments worth $2,398 in total to this clinician.
| Janssen Biotech, Inc. | $271 |
|---|---|
| Merck Sharp & Dohme LLC | $233 |
| Novartis Pharmaceuticals Corporation | $203 |
| Daiichi Sankyo Inc. | $168 |
| AbbVie Inc. | $94.55 |
| AstraZeneca Pharmaceuticals LP | $87.43 |
| GlaxoSmithKline, LLC. | $84.61 |
| Beone Medicines USA, Inc. | $74.72 |
| Food and Beverage | $2,398 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $136,046 in research payments for these studies, mostly to the institutions running them.
- An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 …
AstraZeneca Pharmaceuticals LP - A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lu…
AstraZeneca Pharmaceuticals LP - A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
AstraZeneca UK Limited - An Open label,Single arm, Phase two,Multinational,Multicentre Study to Assess the Efficacy and Safety of five Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive Stage two 3B N…
AstraZeneca UK Limited - CGME751A12301
Hexal AG - A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04622319 - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serou…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.